Skip to main content
Advertisement

Main menu

  • Home
  • Content
    • Current Issue
    • Publication Preview--Ahead of Print
    • Past Issue Archive
    • Case of the Week Archive
    • Classic Case Archive
    • Case of the Month Archive
  • For Authors
  • About Us
    • About AJNR
    • Editors
    • American Society of Neuroradiology
  • Submit a Manuscript
  • Podcasts
    • Subscribe on iTunes
    • Subscribe on Stitcher
  • More
    • Subscribers
    • Permissions
    • Advertisers
    • Alerts
    • Feedback
  • Other Publications
    • ajnr

User menu

  • Subscribe
  • Alerts
  • Log in

Search

  • Advanced search
American Journal of Neuroradiology
American Journal of Neuroradiology

American Journal of Neuroradiology

  • Subscribe
  • Alerts
  • Log in

Advanced Search

  • Home
  • Content
    • Current Issue
    • Publication Preview--Ahead of Print
    • Past Issue Archive
    • Case of the Week Archive
    • Classic Case Archive
    • Case of the Month Archive
  • For Authors
  • About Us
    • About AJNR
    • Editors
    • American Society of Neuroradiology
  • Submit a Manuscript
  • Podcasts
    • Subscribe on iTunes
    • Subscribe on Stitcher
  • More
    • Subscribers
    • Permissions
    • Advertisers
    • Alerts
    • Feedback
  • Follow AJNR on Twitter
  • Visit AJNR on Facebook
  • Follow AJNR on Instagram
  • Join AJNR on LinkedIn
  • RSS Feeds
LetterLETTER

Diffusion-Weighted MR Imaging and MGMT Methylation Status in Glioblastoma: A Reappraisal of the Role of Preoperative Quantitative ADC Measurements

A. Gupta, A. Prager, R.J. Young, W. Shi, A.M.P. Omuro and J.J. Graber
American Journal of Neuroradiology January 2013, 34 (1) E10-E11; DOI: https://doi.org/10.3174/ajnr.A3467
A. Gupta
aDepartment of Radiology Weill Cornell Medical College/New-York Presbyterian Hospital New York, New York
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
A. Prager
bDepartment of Radiology
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
R.J. Young
bDepartment of Radiology
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
W. Shi
cDepartment of Epidemiology and Biostatistics
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
A.M.P. Omuro
dDepartment of Neurology Memorial Sloan-Kettering Cancer Center New York, New York
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
J.J. Graber
eDepartment of Neurology Montefiore Medical Center New York, New York
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Data
  • Info & Metrics
  • References
  • PDF
Loading

Methylation of the DNA repair enzyme O6-methylguanine-DNA-methyltransferase (MGMT) has been well described as one the most significant biomarkers of glioblastoma (GBM) patient prognosis and response to standard first-line chemotherapy treatment with temozolomide.1 As such, we read with great interest the recent study published in AJNR in May 2011 entitled “Apparent Diffusion Coefficient Histogram Analysis Stratifies Progression-Free Survival in Newly Diagnosed Bevacizumab-Treated Glioblastoma” by Dr. Pope and colleagues.2

A significant conclusion of this study was that “lower ADC is associated with tumor MGMT promoter methylation.” This is a finding of significant interest to radiologists and oncologists alike as it suggests that ADC measures can potentially function as both a prognostic and predictive imaging biomarker and thereby act as a surrogate for the reference standard pathologic determination of MGMT methylation status. The authors arrived at this conclusion based on a pixel-by-pixel ADC histogram analysis with bi-modal curve fitting of enhancing tumor in 89 patients with GBM with pathologically confirmed methylation status. This analysis showed a mean ADC of 1071 × 10−6mm2/s for 36 methylated tumors versus 1183 × 10−6mm2/s for 53 unmethylated tumors, with a P value of .01 between the groups.

To assess the applicability of these findings to our own patients, we retrospectively performed blinded quantitative ADC measurements in 105 treatment naïve, preoperative patients with GBM with pathologically confirmed MGMT promoter methylation status determined through real-time methylation specific polymerase chain reaction. Our goal was to build on the work of Pope et al2 by using an ADC quantification technique readily available from a popular vendor and applicable to daily clinical practice. We performed region of interest analysis by using an off-line commercially available workstation (Advantage; GE Healthcare, Milwaukee, Wisconsin) and software (FuncTools 9.04b; GE Healthcare) to calculate quantititative ADC metrics. We drew ROIs around the contrast enhancing tumor and derived ADCmean, ADCmin, and ADCmax values. In addition, by using a validated and commonly used standardized technique,3,4 we manually placed 4 small circular ROIs (30–50 mm2) in the enhancing tumor to select the region of maximal ADC hypointensity and recorded this minimum value as ADCregion of interest. We also obtained ADCratios by dividing ADCregion of interest by ADCnormal with a region of interest placed in normal contralateral brain. Results after Wilcoxon rank-sum tests are summarized in the Table.

View this table:
  • View inline
  • View popup
Table 1:

Relationship between ADC metrics and MGMT status

Unlike Pope et al, 2 in our slightly larger series (n = 105 versus n = 89) by using more widely available postprocessing tools (ADC region of interest analysis on commercially available software versus ADC histogram analysis), we were not able to find a correlation between ADC values and MGMT promoter status (P values >.12). Although our divergent conclusions may in part be related to differences in methods, we suggest that the role of DWI and ADC quantification to predict glioblastoma prognosis and MGMT promoter status requires more investigation and validation before wide adoption into routine clinical practice.

Acknowledgments

The authors gratefully thank Drs. Akash D. Shah, Andrew D. Schweitzer, Jason Huse, and Zhigang Zhang for their contributions to this project.

References

  1. 1.↵
    1. Kim YS,
    2. Kim SH,
    3. Cho J,
    4. et al
    . MGMT gene promoter methylation as a potent prognostic factor in glioblastoma treated with temozolomide-based chemoradiotherapy: a single-institution study. Int J Radiat Oncol Biol Phys 2012;84:661–67
    CrossRefPubMed
  2. 2.↵
    1. Pope WB,
    2. Lai A,
    3. Mehta R,
    4. et al
    . Apparent diffusion coefficient histogram analysis stratifies progression-free survival in newly diagnosed bevacizumab-treated glioblastoma. AJNR Am J Neuroradiol 2011;32:882–89
    Abstract/FREE Full Text
  3. 3.↵
    1. Law M,
    2. Young R,
    3. Babb J,
    4. et al
    . Histogram analysis versus region of interest analysis of dynamic susceptibility contrast perfusion MR imaging data in the grading of cerebral gliomas. AJNR Am J Neuroradiol 2007;28:761–66
    Abstract/FREE Full Text
  4. 4.↵
    1. Wetzel SG,
    2. Cha S,
    3. Johnson G,
    4. et al
    . Relative cerebral blood volume measurements in intracranial mass lesions: interobserver and intraobserver reproducibility study. Radiology 2002;224:797–803
    CrossRefPubMed
  • © 2013 by American Journal of Neuroradiology
PreviousNext
Back to top

In this issue

American Journal of Neuroradiology: 34 (1)
American Journal of Neuroradiology
Vol. 34, Issue 1
1 Jan 2013
  • Table of Contents
  • Index by author
Advertisement
Print
Download PDF
Email Article

Thank you for your interest in spreading the word on American Journal of Neuroradiology.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Diffusion-Weighted MR Imaging and MGMT Methylation Status in Glioblastoma: A Reappraisal of the Role of Preoperative Quantitative ADC Measurements
(Your Name) has sent you a message from American Journal of Neuroradiology
(Your Name) thought you would like to see the American Journal of Neuroradiology web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Diffusion-Weighted MR Imaging and MGMT Methylation Status in Glioblastoma: A Reappraisal of the Role of Preoperative Quantitative ADC Measurements
A. Gupta, A. Prager, R.J. Young, W. Shi, A.M.P. Omuro, J.J. Graber
American Journal of Neuroradiology Jan 2013, 34 (1) E10-E11; DOI: 10.3174/ajnr.A3467

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
Diffusion-Weighted MR Imaging and MGMT Methylation Status in Glioblastoma: A Reappraisal of the Role of Preoperative Quantitative ADC Measurements
A. Gupta, A. Prager, R.J. Young, W. Shi, A.M.P. Omuro, J.J. Graber
American Journal of Neuroradiology Jan 2013, 34 (1) E10-E11; DOI: 10.3174/ajnr.A3467
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One
Purchase

Jump to section

  • Article
    • Acknowledgments
    • References
  • Figures & Data
  • Info & Metrics
  • References
  • PDF

Related Articles

  • Reply:
  • PubMed
  • Google Scholar

Cited By...

  • No citing articles found.
  • Crossref
  • Google Scholar

This article has not yet been cited by articles in journals that are participating in Crossref Cited-by Linking.

More in this TOC Section

  • COVID-19 Related Central Nervous System Vasculopathy: Beyond Vasculitis
  • Reply:
  • Diagnostic Value of “Mushroom” Morphology in Vertebral Chordoma
Show more LETTERS

Similar Articles

Advertisement

News and Updates

  • Lucien Levy Best Research Article Award
  • Thanks to our 2020 Distinguished Reviewers
  • Press Releases

Resources

  • Evidence-Based Medicine Level Guide
  • How to Participate in a Tweet Chat
  • AJNR Podcast Archive
  • Ideas for Publicizing Your Research
  • Librarian Resources
  • Terms and Conditions

Opportunities

  • Share Your Art in Perspectives
  • Get Peer Review Credit from Publons
  • Moderate a Tweet Chat

American Society of Neuroradiology

  • Neurographics
  • ASNR Annual Meeting
  • Fellowship Portal
  • Position Statements

© 2021 by the American Society of Neuroradiology | Print ISSN: 0195-6108 Online ISSN: 1936-959X

Powered by HighWire